Coca-Cola Co (The) (KO) Closes 0.53% Down on the Day for February 05

Equities Staff  |

Dow Jones component Coca-Cola Co (The) (KO) saw its stock move -0.53% to $42.31, representing a per-share move of $0.225, on volume of 11.89 million shares for Friday.

Coca-Cola Co (The) currently has a total float of 4.35 billion shares and moves 14.36 million a day, on average. The stock opened at $42.93 on February 05 and traded between a low of $42.26 and a high of $42.99. The stock now has a 50-day SMA of $42.61 and 200-day SMA of $40.73, and it has a high of $43.91 and low of $36.56 over the last year. Its P/E ratio is 26.8 and its P/B ratio is 7.06.

Coca-Cola Co manufactures, distributes and markets non-alcoholic beverage concentrates and syrups.

Based out of Atlanta, GA, Coca-Cola Co (The) has 129,200 employees and is helmed by CEO Muhtar Kent.

For a deeper dive into the fundamentals of Coca-Cola Co (The), check out’s E.V.A. report for KO.


The Dow Jones Industrial Average is the oldest and most-often cited stock market index for the American equities market. While it’s arguably outdated and inefficient, it remains the most visible representation of the stock market to the outside world. Consisting of 30 companies selected by the editorial board of the Wall Street Journal, it’s meant to give an overview of stock performances by looking at a slice of those mega- and large-cap companies deemed to best represent the broad economy.

The history of the index dates all the way back to 1896 when it was first created by Charles Dow, the legendary founding editor of the Wall Street Journal and founder of Dow Jones & Company, and Edward Jones, a statistician. The price-weighted, scaled index has since become a standard part of most major daily news recaps and has seen dozens of different companies pass through its ranks, with only General Electric (GE) remaining on the index since its inception.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Dr Oliver Krause Founder Untitled Inc Part 2

Matt Bird sits down with Dr Oliver Krause, Founder Untitled Inc, in part 2 of this 2 part interview at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.